North America Anti-Infective Agents Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Range, Route of Administration, Indication, and Distribution Channel

List of Tables

The anti-infective agents market in North America is expected to grow from US$ 45,331.11 million in 2021 to US$ 55,179.54 million by 2028. It is estimated to grow at a CAGR of 3.1% from 2022 to 2028.

The increasing prevalence of chronic diseases is a major factor behind the growth of the North America anti-infective agents market. Chronic diseases are conditions that develop over an extended period due to a combination of genetic, physiological, environmental, and behavioral variables. The four primary categories of NCD are diabetes, cancer, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma), and cardiovascular disorders (including heart attacks and stroke). The rising prevalence of anti-infective resistance, which has now become a public health issue, poses a hazard to human health. Anti-bacterial, anti-viral, anti-fungal, and anti-parasitic drugs are anti-infectives that work to prevent or treat infections. Antibiotics are chemically derived antimicrobial medications that cure and prevent bacterial illnesses by eradicating or preventing their growth. Azithromycin, clarithromycin, and erythromycin are examples of macrolides, which have historically been the main antibiotic classes, studied for their potential role in the secondary prevention of coronary heart diseases.

The study of cancer genesis has advanced to the cellular and molecular levels due to the rapid growth of contemporary science and technology, particularly biomedicine, in the 20th century. Modern cell biology describes malignancies as a group of biological illnesses distinguished by aberrant cell proliferation. Since every cancer begins in a single cell, cancers are also diseases that include alterations in the structure and function of genetic material. Since cancer cells proliferate, they pass on their malignant activity to their offspring (DNA). In the meantime, cancer formation and incidence are also promoted by the invasive growth and spread of cancer cells. One of the most significant classes of antibiotics with their unique inhibitory effects on malignancies is the anti-cancer class. Several antibiotics' anti-proliferative, pro-apoptotic, and anti-epithelial-mesenchymal-transition (EMT) properties have been employed in the treatment of cancer. Thus, the increasing prevalence of chronic diseases is driving the North America anti-infective agents market.

Vendors can attract new customers and expand their footprints in emerging markets with new features and technologies. This factor is likely to drive the North America anti-infective agents market at a good CAGR during the forecast period.

North America Anti-Infective Agents Market Revenue and Forecast to 2028 (US$ Million)

North America Anti-Infective Agents Market Segmentation

The North America anti-infective agents market is segmented based on type, range, route of administration, indication, distribution channel, and country. Based on type, the market is segmented into anti-bacterial, anti-viral, anti-fungal, and others. The anti-viral segment is expected to account for the largest market share by the end of 2022.

Based on range, the market is segmented into broad spectrum and narrow spectrum. By the end of 2022, the narrow spectrum segment will likely hold a larger market share.

Based on route of administration, the market is segmented into topical, oral, IV, and others. By the end of 2022, the IV segment is likely to hold the largest market share.

Based on indication, the market is segmented into HIV, tuberculosis, respiratory infection, pneumonia, and others. In 2022, the others segment is projected to hold the largest share of the market.

Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, e-commerce, and others. By the end of 2022, the hospital pharmacies segment is likely to hold the largest market share.

Based on country, the market is segmented into the US, Canada, and Mexico. The US is expected to hold the largest market share by the end of 2022.

Abbott; Allergan Plc.; Astellas Pharma Inc.; Bayer AG; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Merck & Co., Inc.; and Novartis AG are the leading companies in the North America anti-infective agents market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America anti-infective agents market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America anti-infective agents market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the anti-infective agents market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Product Code: BMIRE00025834

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Anti-Infective Agents Market - By Type
- 1.3.2 North America Anti-Infective Agents Market - By Range
- 1.3.3 North America Anti-Infective Agents Market - By Route of Administration
- 1.3.4 North America Anti-Infective Agents Market - By Indication
- 1.3.5 North America Anti-Infective Agents Market - By Distribution Channel
- 1.3.6 North America Anti-Infective Agents Market - By Country

2. North America Anti-Infective Agents Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Anti-infective Agents Market - Market Landscape

4.1 Overview
4.2 North America PEST Analysis
4.3 Experts Opinion

5. North America Anti-Infectives Agents Market - Key Market Dynamics

5.1 Key Drivers
- 5.1.1 Increasing Prevalence of Chronic Diseases
- 5.1.2 Surging Government Support for Research Activities and Clinical Trials
5.2 Market Restraints
- 5.2.1 Emergence of Anti-infective Drugs Resistance and Their Side Effects
5.3 Market Opportunities
- 5.3.1 Development of New Anti-infective Agents
5.4 Future Trends
- 5.4.1 Rising Investments in R&D Activities in Pharmaceutical Sector
5.5 Impact Analysis

6. Anti-Infectives Agents Market - North America Analysis

6.1 North America Anti-Infectives Agents Market Revenue Forecast and Analysis

7. North America Anti-Infectives Agents Market Analysis and Forecast to 2028 - Type

7.1 Overview
7.2 North America Anti-infectives Agents Market, by Type, 2022 & 2028 (%)
7.3 Anti-Viral
- 7.3.1 Overview
- 7.3.2 Anti-Viral Market Revenue and Forecast to 2028 (US$ Million)
7.4 Anti-Bacterial
- 7.4.1 Overview
- 7.4.2 Anti-Bacterial Market Revenue and Forecast to 2028 (US$ Million)
7.5 Anti-Fungal
- 7.5.1 Overview
- 7.5.2 Anti-Fungal Market Revenue and Forecast to 2028 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others Market Revenue and Forecast to 2028 (US$ Million)

8. North America Anti-Infectives Agents Market Analysis and Forecast to 2028 - Range

8.1 Overview
8.2 North America Anti-Infectives Agents Market, by Range, 2022 & 2028 (%)
8.3 Narrow Spectrum
- 8.3.1 Overview
- 8.3.2 Narrow Spectrum Market Revenue and Forecast to 2028 (US$ Million)
8.4 Broad Spectrum
- 8.4.1 Overview
- 8.4.2 Broad Spectrum Market Revenue and Forecast to 2028 (US$ Million)

9. North America Anti-Infectives Agents Market Analysis and Forecast to 2028 - Route of Administration

9.1 Overview
9.2 North America Anti-Infectives Agents Market, by Route of Administration, 2022 & 2028 (%)
9.3 IV
- 9.3.1 Overview
- 9.3.2 IV Market Revenue and Forecast to 2028 (US$ Million)
9.4 Oral
- 9.4.1 Overview
- 9.4.2 Oral Market Revenue and Forecast to 2028 (US$ Million)
9.5 Topical
- 9.5.1 Overview
- 9.5.2 Topical Market Revenue and Forecast to 2028 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others Market Revenue and Forecast to 2028 (US$ Million)

10. North America Anti-Infectives Agents Market Analysis and Forecast to 2028 - Indication

10.1 Overview
10.2 North America Anti-Infectives Agents Market, by Indication, 2022 & 2028 (%)
10.3 HIV
- 10.3.1 Overview
- 10.3.2 HIV Market Revenue and Forecast to 2028 (US$ Million)
10.4 Tuberculosis
- 10.4.1 Overview
- 10.4.2 Tuberculosis Market Revenue and Forecast to 2028 (US$ Million)
10.5 Respiratory Infection
- 10.5.1 Overview
- 10.5.2 Respiratory Infection Market Revenue and Forecast to 2028 (US$ Million)
10.6 Pneumonia
- 10.6.1 Overview
- 10.6.2 Pneumonia Market Revenue and Forecast to 2028 (US$ Million)
10.7 Others
- 10.7.1 Overview
- 10.7.2 Others Market Revenue and Forecast to 2028 (US$ Million)

11. North America Anti-Infectives Agents Market Analysis and Forecast to 2028 - Distribution Channel

11.1 Overview
11.2 North America Anti-Infectives Agents Market, by Distribution Channel, 2022 & 2028 (%)
11.3 Hospital Pharmacies
- 11.3.1 Overview
- 11.3.2 Hospital Pharmacies Market Revenue and Forecast to 2028 (US$ Million)
11.4 Retail Pharmacies
- 11.4.1 Overview
- 11.4.2 Retail Pharmacies Market Revenue and Forecast to 2028 (US$ Million)
11.5 Specialty Pharmacies
- 11.5.1 Overview
- 11.5.2 Specialty Pharmacies Market Revenue and Forecast to 2028 (US$ Million)
11.6 E-Commerce
- 11.6.1 Overview
- 11.6.2 E-Commerce Market Revenue and Forecast to 2028 (US$ Million)
11.7 Others
- 11.7.1 Overview
- 11.7.2 Others Market Revenue and Forecast to 2028 (US$ Million)

12. North America Anti-Infectives Agents Market Analysis and Forecasts To 2028 - Country Analysis

12.1 Overview
- 12.1.1 North America: Anti-Infective Agents Market, by Country, 2022 & 2028 (%)
  - 12.1.1.1 US: Anti-Infective Agents Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.1.1.1 Overview
    - 12.1.1.1.2 US: Anti-Infective Agents Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.1.1.3 US: Anti-Infective Agents Market, by Type, 2019-2028 (US$ Million)
    - 12.1.1.1.4 US: Anti-Infective Agents Market, by Range, 2019-2028 (US$ Million)
    - 12.1.1.1.5 US: Anti-Infective Agents Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.1.1.6 US: Anti-Infective Agents Market, by Indications, 2019-2028 (US$ Million)
    - 12.1.1.1.7 US: Anti-Infective Agents Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 12.1.1.2 Canada: Anti-Infective Agents Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.1.2.1 Overview
    - 12.1.1.2.2 Canada: Anti-Infective Agents Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.1.2.3 Canada: Anti-Infective Agents Market, by Type, 2019-2028 (US$ Million)
    - 12.1.1.2.4 Canada: Anti-Infective Agents Market, by Range, 2019-2028 (US$ Million)
    - 12.1.1.2.5 Canada: Anti-Infective Agents Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.1.2.6 Canada: Anti-Infective Agents Market, by Indications, 2019-2028 (US$ Million)
    - 12.1.1.2.7 Canada: Anti-Infective Agents Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 12.1.1.3 Mexico: Anti-Infective Agents Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.1.3.1 Overview
    - 12.1.1.3.2 Mexico: Anti-Infective Agents Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.1.3.3 Mexico: Anti-Infective Agents Market, by Type, 2019-2028 (US$ Million)
    - 12.1.1.3.4 Mexico: Anti-Infective Agents Market, by Range, 2019-2028 (US$ Million)
    - 12.1.1.3.5 Mexico: Anti-Infective Agents Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.1.3.6 Mexico: Anti-Infective Agents Market, by Indications, 2019-2028 (US$ Million)
    - 12.1.1.3.7 Mexico: Anti-Infective Agents Market, by Distribution Channel, 2019-2028 (US$ Million)

13. Anti-infectives Agents Market-Industry Landscape

13.1 Overview
13.2 Growth Strategies In The Anti-infective agents Market, 2018-2022
13.3 Organic Developments
- 13.3.1 Overview
- 13.3.2 Organic Growth Strategies In The Anti-infective agents Market, 2018-2022
13.4 Inorganic Developments
- 13.4.1 Overview
- 13.4.2 Inorganic Growth Strategies In The Anti-infective agents Market, 2018-2022

14. Anti-Infectives Agents Market- Company Profiles

14.1 Abbott
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Allergan Plc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Astellas Pharma Inc.
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Merck & Co., Inc.
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Bayer AG
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Bristol-Myers Squibb Company
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Boehringer Ingelheim International GmbH
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 F. HOFFMANN-LA ROCHE LTD.
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Gilead Sciences, Inc.
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 GlaxoSmithKline plc.
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
14.11 Novartis AG
- 14.11.1 Key Facts
- 14.11.2 Business Description
- 14.11.3 Products and Services
- 14.11.4 Financial Overview
- 14.11.5 SWOT Analysis
- 14.11.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms